Institutional Clinical Guidelines
1 MedUni Wien (2024) — Care for ME/CFS Praxisleitfaden
(OG ME/CFS and MedUni Wien 2024)
Key Findings:
Practice guide developed by Medical University of Vienna and Austrian Society for ME/CFS based on PPIE (Patient Public Involvement and Engagement) methodology. Synthesizes data from 687 ME/CFS patients in D-A-CH region (Germany-Austria-Switzerland) via CCCFS questionnaire, plus qualitative surveys from 221 respondents and expert interviews.
Demographic findings: 84% female, 15.6% male; 70% developed ME/CFS before age 40; average diagnostic delay of 5 years. 65% moderate severity, 18% severe/very severe. 65% not working or retired (vs. 86% employed pre-illness).
Treatment efficacy data (from CCCFS survey):
- Most effective: Medications targeting comorbidities (MCAS, PoTS, immune deficiency) with 24–48% reporting phase-wise or sustained improvement
- Low efficacy: Analgesics (60–71% no improvement), antidepressants (67–77% no improvement)
- Key principle: Individual titration essential; no standard dosing fits all ME/CFS patients
Care structure recommendations:
- Specialized interdisciplinary clinics required (none exist in Austria/Switzerland)
- Telemedicine essential for moderate/severe patients
- Home visits necessary for severe/very severe patients
- Case management across health/social systems
- Infection control critical (FFP2 masks, air filters, spacing)
Relevance: First comprehensive institutional guideline from major European academic medical center integrating patient-reported outcomes with clinical expertise. Provides evidence for treatment prioritization (target comorbidities first) and care delivery models. Diagnostic toolbox (Canadian Consensus Criteria, Bell Scale, FUNCAP55, DSQ-PEM) provides standardized assessment framework. Particularly valuable for understanding ME/CFS presentation and needs in German-speaking healthcare contexts.
Certainty Assessment:
- Quality: High (institutional guideline, academic medical center, PPIE methodology)
- Sample: n=687 (CCCFS survey), n=221 (qualitative), n=8 (expert interviews)
- Currency: Very current (June 2024 publication)
- Limitations: Austria-specific healthcare context; CCCFS survey limited to diagnosed patients (selection bias); cross-sectional design; treatment data relies on patient self-report without standardized outcome measures
2 MedUni Wien (2025) — Indikations-Medikamentenliste für PAIS und ME/CFS
(Referenzzentrum Postvirale Syndrome 2025)
Key Findings: Official medication list for ME/CFS and post-acute infection syndromes (PAIS) covered by Austrian health insurance (ÖGK, BVAEB, SVS) as of February 21, 2025. All medications are off-label for ME/CFS indication.
Medication categories:
- Sleep disturbances: Melatonin (sustained-release) 2–4mg
- Mast cell activation (MCAS): H1/H2 blockers, ketotifen, cromolyn sodium
- PoTS tachycardia: Cardioselective beta-blockers (nebivolol), ivabradine
- Orthostatic intolerance: Pyridostigmine 10–60mg, midodrine, fludrocortisone
- Endothelial dysfunction/PEM prevention: Statins (atorvastatin 10mg), magnesium, diosmin
- Microthrombi/circulation: Aspirin 50mg, sulodexide, clopidogrel, ginkgo 80mg
- Cognitive dysfunction (neuroinflammation): LDN 0.5–5mg, LDA 0.25–2mg, fluvoxamine, guanfacin + NAC
Dosing principles emphasized:
- Start lowest dose, titrate slowly
- Discontinue if adverse effects
- ME/CFS patients frequently report medication intolerances
- Trial reduction/discontinuation over time
- No standard schema fits all patients
Relevance: First official institutional medication list for ME/CFS with insurance coverage in a national healthcare system. Validates off-label use of medications commonly prescribed in ME/CFS community but lacking formal guidelines. Particularly significant for: (1) institutionalizing LDN and LDA for cognitive dysfunction, (2) recognizing MCAS and PoTS as core ME/CFS comorbidities requiring treatment, (3) addressing endothelial dysfunction/microthrombi hypothesis with antiplatelet agents. Provides template for systematic approach to symptom-targeted pharmacotherapy when disease-modifying treatments are unavailable.
Certainty Assessment:
- Quality: High (institutional clinical guideline, insurance-endorsed)
- Evidence base: Mix of published literature, clinical experience, and Praxisleitfaden patient survey data
- Currency: Very current (February 2025)
- Regional applicability: Austria-specific insurance coverage; medications available internationally but coverage varies
- Limitations: All off-label use; requires thorough informed consent; compounding pharmacy needed for LDN/LDA; Schellong/tilt-table testing required for PoTS medications